- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - Lynparza approved in EU for prostate cancer
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for biliary tract cancer
AnnouncementREG - AstraZeneca PLC - Enhertu recommended for EU approval in HER2-low BC
AnnouncementREG - AstraZeneca PLC - Update on Imfinzi PEARL trial
AnnouncementREG - AstraZeneca PLC - Imfinzi + Imjudo recommended for approvals in EU
AnnouncementREG - AstraZeneca PLC - Enhertu approved in EU for gastric cancer
AnnouncementREG - AstraZeneca PLC - Forxiga CHMP opinion for symptomatic chronic HF
AnnouncementREG - AstraZeneca PLC - Update on US review of Lynparza PROpel sNDA
AnnouncementREG - AstraZeneca PLC - Capivasertib PFS in HR-positive breast cancer
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - AstraZeneca announces sale of West Chester site
AnnouncementREG - AstraZeneca PLC - AstraZeneca to acquire Neogene Therapeutics
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - AstraZeneca PLC - Imfinzi recommended for approval in the EU for BTC
AnnouncementREG - AstraZeneca PLC - Enhertu recommended for EU approval in gastric
AnnouncementREG - AstraZeneca PLC - Lynparza combo recommended in the EU for mCRPC
AnnouncementREG - AstraZeneca PLC - Imfinzi + Imjudo approved in US for lung cancer
Announcement